ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2036

Damage Trajectories in Systemic Sclerosis Using Group-Based Trajectory Modeling

Ariane Barbacki1, Murray Baron2, Mianbo Wang3, Yuqing Zhang4, Mandana Nikpour5 and Ada Man6, 1McGill University Health Center, Montreal, QC, Canada, 2Jewish General Hospital, Montreal, QC, Canada, 3Lady Davis institute for Medical Research, Montreal, QC, Canada, 4Massachusetts General Hospital, Harvard Medical School, Boston, 5The University of Melbourne at St. Vincent's Hospital, Melbourne, Victoria, Australia, 6University of Manitoba, Winnipeg, MB, Canada

Meeting: ACR Convergence 2020

Keywords: Damage Index, population studies, prognostic factors, Scleroderma

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 9, 2020

Title: Systemic Sclerosis & Related Disorders – Clinical I: Stratification Strategies for Clinical Trials (2033–2037)

Session Type: Abstract Session

Session Time: 3:00PM-3:50PM

Background/Purpose: Systemic sclerosis (SSc) is a rare systemic autoimmune disease associated with a high mortality and characterized by the accrual of organ damage over time. The Scleroderma Clinical Trials Consortium Damage Index (SCTC-DI) is a recently validated tool to measure this damage (Ferdowsi et al., 2019). Identifying predictors of future damage is of utmost importance for prognostication and guiding research. This study aimed to identify if there are distinct trajectories of damage accrual from early in the disease and to determine which variables are associated with different trajectories, which could help guide when to initiate aggressive therapy early.

Methods: Using a prospective cohort design, incident adult cases of SSc (disease onset < 2 years) were identified in two large databases. Patients from these databases are enrolled consecutively and followed with yearly standardized assessments. Patients who met the ACR-EULAR classification criteria for systemic sclerosis with at least two cohort visits and two SCTC-DI values were included. Due to missing data, three elements of the SCTC-DI were removed from the scoring (small joint contractures, pericardial effusion, GAVE). Group-based trajectory modelling (GBTM) was used to identify clusters of patients with similar DI trajectories. Their baseline characteristics were then compared for statistical significance using a one way-analysis of variance (ANOVA) and Kruskal-Wallis Test for continuous variables and chi-square test and Fisher’s exact test for categorical variables.

Results: 409 patients were included in this study. Four trajectories (Figure) of damage accrual were identified, with increasing damage over time and a plateauing effect observed in the three groups with higher damage scores. The average of posterior probabilities of group membership assigned to each group was 0.92, suggesting our trajectory model fits well. The groups were distinct at baseline, with patients who had the fastest damage accrual also having a higher baseline SCTC-DI.  Clinical factors that were more prevalent in the worst damage trajectories were older age, male sex, current or previous smoking history, diffuse disease, tendon friction rubs, renal impairment, anti-RNA polymerase positivity and higher baseline inflammatory markers (Table). Anti-centromere antibody positivity was more prevalent in the lower disease damage groups.

Conclusion: We have identified four distinct trajectories of disease damage in a combined incident cohort of patients with SSc. Several clinical and serological characteristics were more prevalent in those with worse damage trajectories. These findings may be helpful in recognizing patients in whom early aggressive treatment is necessary.


Disclosure: A. Barbacki, None; M. Baron, None; M. Wang, None; Y. Zhang, None; M. Nikpour, Actelion, 2, 5, 8, GSK, 2, 5, 8, Boehringer Ingelheim, 5; A. Man, Boehringer Ingelheim Canada, 5.

To cite this abstract in AMA style:

Barbacki A, Baron M, Wang M, Zhang Y, Nikpour M, Man A. Damage Trajectories in Systemic Sclerosis Using Group-Based Trajectory Modeling [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/damage-trajectories-in-systemic-sclerosis-using-group-based-trajectory-modeling/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/damage-trajectories-in-systemic-sclerosis-using-group-based-trajectory-modeling/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology